BCLT will host a panel discussion of issues of great importance to healthcare and biotechnology: the patentabilty of diagnostic methods and DNA. The discussion will focus on the doctrinal and societal implications of two current cases: Prometheus v Mayo and AMP v Myriad. In the recent Prometheus case, the US Supreme Court held that a claim that covers specific correlations between blood test results and the effectiveness of a drug dosage is not eligible for patent protection. The Myriad case has been remanded to the Federal Circuit for reconsideration in light of Prometheus of the District Court’s ruling that various claims to DNA lack patent-eligibility. The Panel will feature Professor Rebecca Eisenberg of Michigan Law, a noted expert on these issues, whose article was cited by the Supreme Court in Prometheus.
Rebecca S. Eisenberg
University of Michigan Law School
UC Hastings College of the Law
Robert P. Merges
BCLT and Berkeley Law
Weil, Gotshal & Manges LLP
Electronic Frontier Foundation
Morrison & Foerster LLP
A reception will follow the panel discussion.
This event is free and open to the public.
2.0 hours of CLE will be available to attendees.
The Boalt Hall Patent Law Society